Johnson & Johnson (NYSE:JNJ) Shares Acquired by Blue Square Asset Management LLC

Posted by Defense World Staff on Oct 13th, 2023

Blue Square Asset Management LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 171.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,995 shares of the company’s stock after acquiring an additional 6,308 shares during the period. Johnson & Johnson makes up 1.2% of Blue Square Asset Management LLC’s holdings, making the stock its 20th biggest holding. Blue Square Asset Management LLC’s holdings in Johnson & Johnson were worth $1,654,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in JNJ. Atlantic Private Wealth LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $32,000. Ruedi Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $42,000. 25 LLC acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $55,000. Horizons Wealth Management grew its holdings in shares of Johnson & Johnson by 1,730.0% in the second quarter. Horizons Wealth Management now owns 366 shares of the company’s stock valued at $61,000 after purchasing an additional 346 shares in the last quarter. Finally, Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $66,000. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.1 %

JNJ stock opened at $156.32 on Friday. The company has a fifty day moving average price of $163.35 and a 200 day moving average price of $162.41. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The company has a market cap of $406.27 billion, a price-to-earnings ratio of 31.64, a price-to-earnings-growth ratio of 3.21 and a beta of 0.55. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s revenue was up 6.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.59 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were paid a $1.19 dividend. The ex-dividend date was Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 3.05%. Johnson & Johnson’s dividend payout ratio is currently 96.36%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on JNJ shares. Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Royal Bank of Canada initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, October 4th. They issued an “outperform” rating and a $178.00 price target for the company. Finally, Wells Fargo & Company decreased their price target on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a research note on Thursday, August 31st. Nine equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $171.39.

Read Our Latest Report on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.